Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
31
03
2020
revised:
05
05
2020
accepted:
11
05
2020
pubmed:
6
7
2020
medline:
6
7
2020
entrez:
5
7
2020
Statut:
ppublish
Résumé
Programmed cell death-ligand 2 (PD-L2) is one of the two ligands of the programmed cell death-1 (PD-1) receptor, an inhibitory protein mainly expressed on activated immune cells that is targeted in the clinic, with successful and remarkable results. The PD-1/PD-Ls axis was shown to be one of the most relevant immunosuppressive pathways in the immune microenvironment, and blocking this interaction gave rise to an impressive clinical benefit in a broad variety of solid and hematological malignancies. Although PD-L2 has been historically considered a minor ligand, it binds to PD-1 with a two- to six-fold higher affinity as compared to PD-L1. PD-L2 can be expressed by immune, stromal, or tumor cells. The aims of this narrative review are to summarize PD-L2 biology in the physiological responses of the immune system and its role, expression, and clinical significance in cancer.
Identifiants
pubmed: 32622310
pii: S1936-5233(20)30303-X
doi: 10.1016/j.tranon.2020.100811
pmc: PMC7332529
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100811Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Cancer Treat Rev. 2017 Feb;53:138-145
pubmed: 28113097
Cancer Sci. 2019 Sep;110(9):2711-2721
pubmed: 31294893
Oncoimmunology. 2018 Nov 20;8(2):e1541535
pubmed: 30713802
Exp Mol Pathol. 2019 Aug;109:1-15
pubmed: 30953647
Lancet Oncol. 2019 Mar;20(3):371-382
pubmed: 30765258
Clin Cancer Res. 2019 Aug 1;25(15):4808-4819
pubmed: 31076547
Eur J Immunol. 2002 Mar;32(3):634-43
pubmed: 11857337
Cancer Treat Rev. 2017 Jun;57:8-15
pubmed: 28525810
J Transl Med. 2018 Apr 4;16(1):87
pubmed: 29615063
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Sci. 2016 Jun;107(6):726-33
pubmed: 27015293
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Ann Surg Oncol. 2019 Jun;26(6):1925-1933
pubmed: 30815803
Front Oncol. 2018 Jul 13;8:269
pubmed: 30057891
Front Immunol. 2018 Oct 01;9:2241
pubmed: 30327652
Gastroenterology. 2018 Sep;155(3):784-798
pubmed: 29885883
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):180-185
pubmed: 26621196
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777
pubmed: 27837027
QJM. 2019 Jun 26;:
pubmed: 31250021
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Int J Mol Sci. 2019 Apr 29;20(9):
pubmed: 31035644
J Clin Invest. 2018 Nov 1;128(11):5185
pubmed: 30382943
Immunity. 2014 Dec 18;41(6):1026-39
pubmed: 25526313
Front Immunol. 2019 Apr 24;10:847
pubmed: 31068935
Eur J Immunol. 2007 Sep;37(9):2405-10
pubmed: 17683117
J Allergy Clin Immunol. 2016 Jan;137(1):314-318.e5
pubmed: 26299988
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Cancers (Basel). 2019 Mar 05;11(3):
pubmed: 30841554
Target Oncol. 2018 Apr;13(2):113-123
pubmed: 29470785
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Int J Gynecol Pathol. 2019 Sep;38(5):404-413
pubmed: 30134343
Drugs. 2019 Apr;79(5):573-578
pubmed: 30805896
Crit Rev Oncol Hematol. 2018 Jun;126:135-144
pubmed: 29759556
Cancer Immunol Res. 2015 Oct;3(10):1123-1129
pubmed: 26081225
Ann Surg Oncol. 2019 Jun;26(6):1916-1924
pubmed: 30815801
Nat Commun. 2018 Mar 5;9(1):948
pubmed: 29507342
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Oncoimmunology. 2017 May 16;6(7):e1327494
pubmed: 28811964
Hum Pathol. 2016 Jul;53:25-34
pubmed: 26980034
Chin J Cancer. 2017 Jul 29;36(1):61
pubmed: 28754154
J Clin Invest. 2013 Jul;123(7):2873-92
pubmed: 23778140
J Exp Med. 2014 May 5;211(5):943-59
pubmed: 24752301
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
Crit Rev Oncol Hematol. 2017 Feb;110:106-116
pubmed: 28109400
Adv Exp Med Biol. 2018;1060:115-129
pubmed: 30155625
Mod Pathol. 2019 Sep;32(9):1344-1358
pubmed: 30996253
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Clin Exp Immunol. 2017 Jun;188(3):420-429
pubmed: 28052400
Oncotarget. 2017 Oct 24;8(60):101994-102005
pubmed: 29254220
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
Breast. 2017 Oct;35:142-150
pubmed: 28735162
Onco Targets Ther. 2014 Apr 12;7:567-73
pubmed: 24748806
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Semin Oncol. 2019 Aug - Oct;46(4-5):372-379
pubmed: 31733828
J Clin Oncol. 2019 Dec 1;37(34):3300-3309
pubmed: 31461379
Nat Commun. 2019 Jun 24;10(1):2764
pubmed: 31235699
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
J Immunol. 2003 Apr 1;170(7):3637-44
pubmed: 12646628
Cancer Immunol Res. 2017 Nov;5(11):1046-1055
pubmed: 29038297
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Immunity. 2014 Dec 18;41(6):1013-25
pubmed: 25526312
J Immunol. 2017 Sep 15;199(6):2020-2029
pubmed: 28768724
Gastroenterology. 2008 Oct;135(4):1228-1237, 1237.e1-2
pubmed: 18760278
J Immunol. 2019 Feb 1;202(3):704-713
pubmed: 30567732
Oncoimmunology. 2017 Nov 1;7(2):e1390641
pubmed: 29308318
Cell Rep. 2019 Dec 10;29(11):3435-3447.e4
pubmed: 31825827
Crit Rev Oncol Hematol. 2017 Dec;120:13-21
pubmed: 29198327
Leukemia. 2014 Sep;28(9):1784-92
pubmed: 24691076
Oncologist. 2015 Nov;20(11):1253-60
pubmed: 26424759
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
Crit Rev Oncol Hematol. 2019 Oct;142:35-43
pubmed: 31357142
J Immunol. 2007 May 1;178(9):5552-62
pubmed: 17442937
ESMO Open. 2017 Nov 14;2(5):e000255
pubmed: 29177095
Semin Oncol. 2018 Jun;45(3):181-186
pubmed: 30352754
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Mol Cancer Ther. 2018 Mar;17(3):710-716
pubmed: 29440293
PLoS One. 2017 Aug 29;12(8):e0183877
pubmed: 28850584
Cancer Commun (Lond). 2019 Jun 3;39(1):30
pubmed: 31159869
Onco Targets Ther. 2017 Jun 13;10:2983-2992
pubmed: 28652780
Oncotarget. 2017 Jul 18;8(38):64066-64082
pubmed: 28969052
Cancers (Basel). 2019 Aug 20;11(8):
pubmed: 31434339
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Hum Pathol. 2016 Jan;47(1):78-84
pubmed: 26541326
J Immunol. 2018 Apr 15;200(8):2592-2602
pubmed: 29531164
JCI Insight. 2017 Jun 2;2(11):
pubmed: 28570278
Med Oncol. 2017 May;34(5):71
pubmed: 28353093
BMC Cancer. 2019 Apr 16;19(1):360
pubmed: 30992011
BMC Cancer. 2018 Jul 28;18(1):766
pubmed: 30055582
Front Immunol. 2017 Oct 30;8:1412
pubmed: 29163490
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Pancreas. 2018 Oct;47(9):1123-1129
pubmed: 30153220
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
ESMO Open. 2019 Jun 12;4(Suppl 3):e000501
pubmed: 31275617
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Commun Biol. 2019 Mar 22;2:109
pubmed: 30911684
Pathobiology. 2016;83(5):267-75
pubmed: 27225345
Oncoimmunology. 2017 Aug 4;6(11):e1358332
pubmed: 29147618
Nat Immunol. 2010 Jun;11(6):535-42
pubmed: 20453843
Anticancer Res. 2017 Mar;37(3):1417-1424
pubmed: 28314313
Cancer Immunol Immunother. 2015 Nov;64(11):1407-17
pubmed: 26201938
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Ann Transl Med. 2019 Sep;7(18):435
pubmed: 31700871
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Oncoimmunology. 2016 Sep 20;5(11):e1235107
pubmed: 27999753
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
PLoS One. 2019 Jun 4;14(6):e0217991
pubmed: 31163080
Front Immunol. 2019 Mar 19;10:511
pubmed: 30941141
Cancer Res Treat. 2017 Jan;49(1):246-254
pubmed: 27456947
J Natl Cancer Inst. 2019 Aug 1;111(8):772-781
pubmed: 31106827